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We asked whether key morphogenetic signaling pathways interact with 22q11 gene dosage to modulate the
severity of cranial or cardiac anomalies in DiGeorge/22q1 deletion syndrome (22q11DS). Sonic hedgehog
(Shh) and retinoic acid (RA) signaling is altered in the brain and heart—clinically significant 22q11DS pheno-
typic sites—in LgDel mouse embryos, an established 22q11DS model. LgDel embryos treated with cyclopa-
mine, an Shh inhibitor, or carrying mutations in Gli3Xtj, an Shh-signaling effector, have morphogenetic
anomalies that are either not seen, or seen at significantly lower frequencies in control or single-mutant
embryos. Similarly, RA exposure or genetic loss of RA function via heterozygous mutation of the RA synthet-
ic enzyme Raldh2 induces novel cranial anomalies and enhances cardiovascular phenotypes in LgDel but not
other genotypes. These changes are not seen in heterozygous Tbx1 mutant embryos—a 22q11 gene thought
to explain much of 22q11DS pathogenesis—in which Shh or RA signaling has been similarly modified. Our
results suggest that full dosage of 22q11 genes beyond Tbx1 establish an adaptive range for morphogenetic
signaling via Shh and RA. When this adaptive range is constricted by diminished dosage of 22q11 genes,
embryos are sensitized to otherwise benign changes in Shh and RA signaling. Such sensitization, in the
face of environmental or genetic factors that modify Shh or RA signaling, may explain variability in
22q11DS morphogenetic phenotypes.
INTRODUCTION
DiGeorge or 22q11 deletion syndrome (22q11DS) is the con-
sequence of a hemizygous loss of a ‘critical’ (1.5 Mb) or larger
‘typical’ (3 Mb) region of human Chr.22 (1). Clinically signifi-
cant 22q11DS phenotypes vary in penetrance and severity.
They include modest to life-threatening cardiovascular malfor-
mations (2,3), mild-to-severe craniofacial and limb anomalies
(2), parathyroid and thymic hypoplasia (4) and increased sus-
ceptibility to a range of behavioral and psychiatric disorders
from autism and intellectual disability to schizophrenia (5).
Despite compelling clinical data on varying frequency and
severity of 22q11DS phenotypes, there is little mechanistic
insight into why shared genomic lesions result in variable
outcomes (6,7). Accordingly, we asked whether key morpho-
genetic signaling pathways, whose activity and influence
may vary at 22q11DS phenotypic sites, interact with dimin-
ished 22q11 gene dosage to modulate the severity of cranial
or cardiac anomalies.
Initial differentiation at all 22q11DS phenotypic sites,
including the brain and heart, depends upon morphogenetic
interactions between mesenchymal and epithelial tissues
mediated by diffusible signals including sonic hedgehog
(Shh), retinoic acid (RA), fibroblast growth factors (Fgfs)
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and bone morphogenetic proteins (Bmps) (8). Coincident
expression of 22q11 genes with these signals in the brain,
heart, face and limbs (9–11) suggests that Shh, RA, Fgfs,
and Bmps are potential modifiers of 22q11DS phenotypes.
Indeed, some phenotypes in mutant mice with genetic disrup-
tion of RA (Raldh2) and Fgf8 signaling have been identified as
22q11DS ‘phenocopies’ (12,13), whereas the consequences of
Shh and Bmp signaling anomalies are more narrowly inter-
preted as ‘parallel’ to 22q11DS (14,15). It is unclear,
however, whether such similarities reflect linear effects on
common downstream targets consistent with ‘phenocopy’, or
more complex interactions between local signals and 22q11
gene dosage. Shh and RA apparently regulate expression of
at least one 22q11 gene, Tbx1 (16,17). Tbx1, when deleted
in combination with Crkl (outside the critical region, but
within the typical region; 1), modulates RA and Fgf8 signaling
(18), while total loss of Tbx1 function down-regulates Bmp4
(19). Moreover, mutations in RA- as well as Fgf8- and
Bmp-associated signaling genes modulate Tbx1 mutant pheno-
types (20–23). Tbx1 has been robustly associated with several
22q11DS anomalies including aortic arch, thymus and palatal
anomalies (24–26). Nevertheless, the role of Tbx1 in the full
22q11DS spectrum remains uncertain (9,27–29). Thus, we
compared the consequences of broader 22q11 deletion
versus heterozygous Tbx1 mutation for altering key morpho-
genetic signaling pathways and essential 22q11DS pheno-
types.
We found that interactions between Shh or RA signaling
and 22q11 gene dosage enhance 22q11DS-related phenotypes
in the LgDel mouse 22q11DS model but not Tbx1 mutant
mice. Alterations of Shh or RA signaling that are otherwise
benign yield more frequent and severe cranial or cardiovascu-
lar anomalies in LgDel mice. Our results do not support
simple, linear relationships between morphogenetic signals
and 22q11 genes. Instead, 22q11 gene dosage, Shh and RA
likely participate in broader homeostatic networks that modu-
late a dynamic range of signaling for adaptive morphogenesis
in the brain, heart and other 22q11DS phenotypic sites.
Disruption of these networks by environmental factors or
genetic polymorphisms may be an essential contributor to
phenotypic variability in 22q11DS.
RESULTS
Diminished 22q11 dosage disrupts inductive signaling
pathway gene expression
22q11 gene dosage might influence Shh, RA, Fgf or Bmp sig-
naling at 22q11DS phenotypic sites during initial morphogen-
esis. To assess this potential relationship, we used quantitative
PCR to compare expression levels of a subset of Shh, Fgf or
Bmp ligands, RA synthetic enzymes, as well as receptors
and co-factors for each signal—all with selective expression
at 22q11DS phenotypic sites (8)—in LgDel, Tbx1+/2 and
wild-type (WT) littermate embryos for each genotype at
embryonic day (E) 10.5, a critical stage for morphogenetic
interactions.
Nine of 10 representative Shh-signaling genes are dimin-
ished by 18–25% in the E10.5 LgDel embryo: Shh itself,
the Ptc1 co-receptor, Smo, an intracellular mediator, Gli1,
Gli2 and Gli3 transcriptional activator/repressors, and
co-factors Hhip, Sufu and Boc (n ¼ 7 LgDel, 7 WT; 8 genes
P ≤ 0.05; 2 trends, P ≤ 0.06; Fig. 1). Five of nine representa-
tive RA-signaling genes are diminished by 28–32%: synthetic
enzymes Raldh2 and Raldh3, RA receptors Rara and Rarb
and the RA catabolic enzyme Cyp26a1 (n ¼ 7 LgDel, 7 WT;
4 genes P ≤ 0.05; 1 trend P ≤ 0.06). Two of eight Fgf-related
genes decline: the Fgf receptor Fgfr1 and the Fgf target
Mkp3 (10–18%; n¼ 7 LgDel, 7 WT; 1 gene, P ≤ 0.05; 1 trend
P ≤ 0.06). Finally, six of 13 Bmp-related genes are diminished
by 21–39%: four ligands (Bmp2, 4, 5 and 7), the activin recep-
tor 1 Acvr1 (a non-selective Tgfb receptor), the Bmp receptor
Bmpr1 and the non-selective transcriptional mediator Smad4
(n ¼ 7 LgDel, 7 WT; 6 genes P ≤ 0.05).
Figure 1. Divergent expression levels of Shh, RA, Fgf and Bmp-related signaling genes assessed by qPCR in whole E10.5 LgDel and Tbx1+/2 and WT littermate
control embryos. (A) Among 40 candidates, there is significantly diminished expression (relative to WT littermates) of seven Shh-related genes (solid yellow
bars; see text for ‘n’ and P-values), with two additional genes showing a trend toward significant decline (hatched yellow bars). There are RA signaling genes that
decline significantly (solid purple bars), plus one additional significant trend (hatched purple bar). One Fgf-related declines significantly (solid red bar), and
another shows a significant trend (hatched red bar). Six Bmp-related genes decline significantly (solid blue bars). (B) Signaling gene expression in E10.5
Tbx1+/2 embryos does not mirror LgDel changes. There is modest but statistically significant diminished expression of two RA-related genes (solid purple
bars), only one of which (Rarb) also declines significantly in the LgDel.
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Tbx1 has been proposed as a key, if not singularly explana-
tory, 22q11 gene for 22q11DS phenotypes: including aberrant
heart and brain development (23,30,31). If Tbx1 alone is
responsible for 22q11DS phenotypes, and if they reflect
altered Shh, RA, Bmp or Fgf signaling as suggested
(18,32,33), one would expect significant overlap between
Shh, RA, Bmp or Fgf signaling gene expression changes in
Tbx1+/2 and LgDel embryos. Of 40 signaling-related genes
we assessed, only two are significantly altered in Tbx1+/2
versus 22 in LgDel embryos (n ¼ 9 Tbx1+/2; 6 WT;
Fig. 1B). Both are RA-signaling genes: Raldh1 (16% decrease;
P ≤ 0.02; not altered in LgDel) and Rarb (17% decrease; P ≤
0.04; 31% decrease in LgDel). Only Rarb is changed in both
Tbx1+/2 and LgDel embryos; however, the magnitude is sig-
nificantly greater in LgDel embryos (P ≤ 0.04; n ¼ 7 LgDel, 9
Tbx1+/2). There are no significant expression differences for
WT littermates of LgDel versus Tbx1+/2 embryos of key sig-
naling genes, indicating that expression changes are unlikely
due to genetic background effects (Supplementary Material,
Fig. S1). The significant changes we identify for both LgDel
and Tbx1+/2 embryos are all decreased expression—including
the expected 50% decrement of Tbx1 itself. We note, however,
that we detect increased expression of some of these genes in
distinct regions, or in response to pharmacological or genetic
manipulation in the LgDel (see in what follows). Apparently,
diminished 22q11 gene dosage beyond Tbx1 distinctly alters
morphogenetic signaling gene expression in the LgDel model
of 22q11DS.
Diminished 22q11 dosage alters Shh and RA signaling
The decline in the expression of signaling pathway intermedi-
ates does not necessarily mean that signaling via these path-
ways is altered. Thus, we measured local, independent
‘output’ of Shh and RA signaling—two pathways highly
related to 22q11 genes based on previous observations (16–
18)—in the head/forebrain and heart in LgDel as well as
Tbx1+/2 embryos. We focused on signaling levels at these
sites, and excluded regions like the spinal cord and limb bud
where Shh and RA signaling is robust, but 22q11DS pheno-
types are less well defined. Thus, we can determine whether
there are regional differences in the consequences of dimin-
ished 22q11 gene expression for morphogenetic signaling at
distinct locations known to be compromised in 22q11DS.
For Shh, we crossed a ‘knock-in’ Ptch2:b-galactosidase
(bgal) reporter (34) into LgDel and Tbx1+/2 to visualize
and quantify local signaling independent of mRNA levels,
which may vary based upon stability. There are neither
visible changes in Ptch2:bgal patterns nor quantifiable
changes in activity (measured by soluble bgal in dissected
samples) in the LgDel head/forebrain (Fig. 2A and B, top),
and there are no changes in Ptch2, Shh or Gli1 mRNA
levels (n ¼ 8 LgDel, 9 WT; Fig. 2C, top). In contrast,
Ptch2:bgal expression expands in the LgDel heart/aortic
arches (Fig. 2A and B, bottom), and we detect a 25% increase
in soluble bgal activity in isolated samples of the cardiac
region (n ¼ 5 LgDel, 5 WT; P ≤ 0.05, Fig. 2B). We found a
parallel increase of Ptch2 mRNA (45%; n ¼ 7 LgDel, 9
WT; P ≤ 0.01), and Shh itself is increased by 57% (n ¼ 7
LgDel, 7 WT; P ≤ 0.019; Fig. 2C). These changes are not
seen in Tbx1+/2 embryos for Ptch2:bgal activity (n ¼ 5
Tbx1+/2; 4 WT; Fig. 2D and E) or Ptch2, Shh or additional
Shh-related signaling genes (n ¼ 7 Tbx1+/2; 9 WT; Fig. 3F
and data not shown).
To measure RA signaling, we bred an RA-indicator trans-
gene (DR5-RARE; 35), which is quantitatively sensitive to
altered RA levels (Supplementary Material, Fig. S2), into
LgDel and Tbx1+/2 embryos. In LgDel embryos, DR5-
RARE-dependent RA signaling appears modestly diminished,
based upon altered intensity and extent of bgal labeling, in the
head/forebrain and heart/aortic arches (Fig. 3A). In parallel,
RA signaling levels (soluble bgal activity in dissected
samples) decrease modestly but significantly in the head/
forebrain (12%; n ¼ 6 LgDel; 6 WT; P ≤ 0.05) and heart
(15%; P ≤ 0.05, Fig. 3B). Expression levels of RA synthetic
Figure 2. Shh signaling is increased in the developing heart in LgDel, but not
Tbx1+/2 E10.5 embryos. Embryos in (A) and (D) carry a b-galactosidase
(bgal) reporter under the control of the endogenous Ptch2 promoter. (A) Com-
parison of Ptch2: bgal labeling in the head/forebrain (fb, including the eye, e;
top panels; dotted line indicates site of dissection) and heart/aortic arches (H/
AA; dotted lines indicated site of dissection) of E10.5 WT (left) and LgDel
embryos (right). bgal labeling in the nascent heart and aortic arches (arrow-
heads) is less extensive in WT than LgDel embryos (8 LgDel, 10 WT
embryos analyzed). There is no apparent change in the forebrain/head.
Dotted lines in left hand panels indicate regions dissected for quantitative mea-
surements. (B) Increased Ptch2 promoter activation in the heart and aortic
arches of the LgDel embryos, without change in the head/forebrain, assessed
by soluble bgal levels (ONPG assay, see Materials and Methods). (C)
Increased Ptch2 and Shh mRNA levels in the LgDel heart and aortic arches
(H/AA; solid yellow bars; LgDel values plotted as fold change from WT
values ¼ 1), but not in the head/forebrain. (D) No visible difference in
cranial or cardiac bgal labeling in WT and Tbx1+/2 E10.5 embryos. (E)
Equivalent levels of bgal activity in the head/forebrain and heart/aortic
arches of WT and Tbx1+/2 embryos. (F) No significant change in Shh or
Ptch2 expression in either head or heart of Tbx1+/2 embryos.
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enzymes and receptors parallel these changes (Fig. 3C);
Raldh2 declines significantly in the heart (37%; n ¼ 7
LgDel, 7 WT; P ≤ 0.04) and Rarb declines significantly in
both the head/forebrain and heart (32 and 56%, respectively;
n ¼ 7 LgDel, 7 WT; P ≤ 0.05). In contrast, in Tbx1+/2
embryos, DR5-RARE: bgal activity does not change signifi-
cantly at either site (n ¼ 6 Tbx1+/2; 4 WT; Fig. 3D and E).
There are no significant changes in the expression levels
of Raldh2 and Rarb in the head/forebrain of Tbx1+/2
embryos; however, Raldh2 declines significantly in the
heart (22%, n ¼ 7 Tbx1+/2, 9 WT; P ≤ 0.003), in parallel
with that in the LgDel.
Together, these results establish modest but statistically sig-
nificant changes as well as local variation of Shh and RA sig-
naling at key 22q11DS phenotypic sites—the forebrain/head
and heart in LgDel, but not Tbx1+/2, embryos. In one
case—Shh signaling in the heart—local changes are distinct
from those detected in whole embryos (Fig. 1). In contrast,
changes of RA signaling and related gene expression in the
forebrain/head and heart parallel those measured in the
whole embryo.
Shh, RA, Fgf and Bmp signaling influence 22q11 gene
expression
Morphogenetic signaling is interactive and homeostatic—
signals influence and are modulated by multiple target
genes—perhaps to adjust for individual genetic and environ-
mental variation (36,37) including subtle changes in signaling
like those we found in LgDel embryos. Given the coincident
expression of multiple 22q11 genes and morphogenetic
signals, it is possible that Shh, RA, Fgfs or Bmps regulate ex-
pression of 22q11 genes beyond Tbx1 (16,17). Thus, we asked
if morphogenetic signals regulate 22q11 gene expression
during early embryogenesis.
We did an initial comparison of mRNA levels of 22 22q11
genes selectively expressed at 22q11DS phenotypic sites (11)
in whole E10.5 embryos carrying constitutive loss- and
gain-of-function mutations for morphogenetic signals, or
after acute exposure to function blocking agents (a total of
11 genetic or pharmacological manipulations for which we
measured expression of 22 22q11 genes plus several controls;
n ¼ 3 for each mutation or manipulation; Supplementary
Material, Fig. S3). This initial analysis identified a subset of
genes for each signaling pathway that are consistently and
substantially altered by loss or gain of function. From this
subset, we selected a small group of 22q11 genes for in situ
hybridization (ISH) combined with further qPCR analysis to
determine whether local patterns of 22q11 gene expression
change in response to pharmacologically increased or
decreased morphogenetic signaling in WT embryos. For
each of four 22q11 genes (Fig. 4), we saw local expression
level changes at 22q11DS phenotypic sites (ISH performed
on sets of WT treated and untreated embryos in the same
vials; n ≥ 4 WT and treated embryos for each gene) whose
direction and magnitude is consistent with qPCR measure-
ments. Expression patterns of these genes were not dramatic-
ally expanded or contracted and there were no novel or ectopic
expression domains. For some genes, however, expression
level changes were not uniform at all 22q11DS phenotypic
sites—for example, there is increased Ranbp1 labeling in the
frontonasal process and limb, but not branchial arches or
heart following cyclopamine exposure (Fig. 4, top). Evaluation
following FgfR inhibition is complicated by altered growth at
22q11DS phenotypic sites (Fig. 4, middle). Together, these
results show that some regulation of 22q11 genes by Shh,
RA, Fgf and Bmp is possible. This regulation, however,
likely reflects local modulation of expression levels—or
overall growth—at 22q11DS phenotypic sites rather than sub-
stantial changes in patterning of the embryo.
22q11 gene dosage and Shh signaling interact during
morphogenesis
Our data suggest that interactions between 22q11 gene dosage
and local signals influence morphogenesis at 22q11DS pheno-
typic sites. Environmental or genetic changes, beyond 22q11
deletion but acting on shared targets, could lead to enhanced,
diminished or novel phenotypes. Alternately, additional dis-
ruption of 22q11 gene expression by dis-regulated signaling
might yield loss of function, or dosage rescue of one or
more of 22q11 genes with parallel key 22q11DS phenotypic
Figure 3. Diminished RA signaling in the head/forebrain and heart/aortic
arches in LgDel, but not Tbx1+/2 E10.5 embryos. Embryos in (A) and (D)
carry DR5-RARE:bgal RA reporter transgene. (A) bgal labeling in the fore-
brain (fb) and eye (e; top panels) and the heart/aortic arches (H/AA; dotted
lines) in E10.5 WT and LgDel embryos. bgal labeling is diminished in the
forebrain/head (compare arrowheads, top right) and aortic arches (compare
arrowheads, bottom right) of LgDel versus WT (9 WT and 6 LgDel
embryos analyzed). (B) Diminished bgal activity in dissected LgDel head
and heart based upon soluble bgal assays (ONPG). (C) Rarb expression
declines significantly in the forebrain/head in LgDel embryos, while both
Raldh2 and Rarb expression decline in the heart (solid purple bars). (D) No
visible differences in cranial or cardiac bgal labeling in Tbx1+/2 versus
WT embryos. (E) bgal activity (ONPG assay) is statistically equivalent in
Tbx1+/2 and WT littermates (F) Expression levels of Raldh2 and Rarb in
the head and heart are statistically indistinguishable in Tbx1+/2 and WT litter-
mates.
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changes. Thus, we altered Shh signaling levels in LgDel and
WT littermates between E8.5 and E10.5 with sub-teratogenic
doses of cyclopamine (38) or Shh and Gli3 mutations, and
assessed consequences for morphogenesis and gene expression.
Cyclopamine-exposed LgDel embryos are far more compro-
mised than WT littermates (Fig. 5A; n ¼ 9 LgDel, 8 WT, two
litters). Most cyclopamine-treated LgDel embryos (77%) fail
to develop limb buds, aortic or branchial arches, olfactory
placodes, eyes and forebrains, whereas cyclopamine-treated
WT embryos, even though some are dysmorphic, develop
these structures. In parallel, there is an equivalent decline (80%)
of Shh-regulated Ptch2 in LgDel and WT embryos (Fig. 5B;
n¼ 3 LgDel, 3 LgDel + cyclo., 3 WT, 3 WT + cyclo.).
Figure 5. Response of WT, LgDel and Tbx1+/2 embryos to diminished
Shh signaling due to 48 h cyclopamine exposure. (A) Consequences of
cyclopamine-mediated decline of Shh signaling in LgDel versus WT litter-
mates. LgDel embryos have far more severe and frequent morphogenetic
anomalies at sites of M/E interaction (fb, ba, aah, lb). Numbers of embryos
with similar severity of disrupted development are shown in brackets next
to each example. (B) Transcriptional responses of four Shh-related signaling
genes whose expression is modulated by altered Shh signaling (significant dif-
ferences indicated with brackets and asterisks). (C) In LgDel embryos, cyclo-
pamine does not significantly diminish expression of most 22q11 genes, with
the exception of Zdhhc8, beyond the 50% decrement seen in LgDel alone. (D)
Consequences of cyclopamine-mediated decline in Shh signaling for Tbx1+/2
versus WT littermate embryos. Although there is some variation in size, there
are no noticeable changes in differentiation of non-axial structures.
Figure 4. Morphogenetic signals regulate levels of 22q11 gene expression.
Representative E10.5 whole embryo in situ hybridization (ISH) shows expres-
sion patterns and intensity for four 22q11 genes in WT embryos (left) and WT
embryos treated pharmacologically to diminish Shh (cyclopamine), RA
(DEAB), Fgf (FgfRi) or Bmp (dorsomorphin) signaling. For each gene WT
control and WT treated embryos were hybridized and reacted for labeling in
the same vials to insure absolutely identical conditions. Sites of mesenchy-
mal/epithelial (M/E) interaction and 22q11DS phenotypes are indicated in
the WT control embryo, top left: fb, forebrain; ba, branchial arches; h,
heart; lb, limb bud. Black arrowheads indicate instances when expression
levels change at some M/E 22q11DS phenotypic sites but not others. At
right, mRNA levels in whole WT embryos treated pharmacologically with
cyclopamine, DEAB, FgfRi or dorsomorphin have been measured using
qPCR for each gene whose expression is localized using ISH. Asterisks indi-
cate statistically significant differences.
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Additional Shh signaling genes, however, are significantly
more diminished in cyclopamine-exposed LgDel embryos, in-
cluding Ptch1 (93% LgDel; 68% WT; P ≤ 0.01), Smo (96%
LgDel; 88% WT; P ≤ 0.02) and Gli1 (90% LgDel; 75%
WT; P ≤ 0.003). In contrast, 22q11 gene expression—except
for Zdhhc8 (for which homozygous deletion does not result
in obvious morphogenetic change; 39)—is not diminished
beyond 50% in cyclopamine treated LgDel embryos
(Fig. 5C; n ¼ 3 LgDel + cyclo., 3 LgDel; P ≤ 0.0002 for
Zdhhc8), including 22q11 genes that change in response to
cyclopamine in WT embryos (Fig. 4 and Supplementary
Material, Fig. S3). Finally, cyclopamine-treated Tbx1+/2
embryos do not differ morphologically from WT littermates
(n ¼ 7 Tbx1+/2; n ¼ 9 WT embryos from two litters;
Fig. 5D). Apparently, diminished 22q11 gene dosage—
beyond Tbx1—sensitizes mid-gestation embryos to
deleterious effects of substantially reduced Shh activity.
Cyclopamine-induced dysmorphology in WT embryos from
Tbx1 litters is less noticeable than in WT embryos from
LgDel litters, independent of genetic background (Fig. 5D).
This may reflect systemic maternal responses due to the
resorption of cyclopamine-exposed LgDel embryos that also
compromise WT littermates (40,41).
We confirmed this apparent interaction between Shh and
22q11 dosage genetically using Shh+/2 (42), Gli3+/Xtj and
Gli3Xtj/Xtj (43) mutants in combination with LgDel. For rigor-
ous assessment of phenotypic modulation, we quantified a
specific 22q11DS morphogenetic phenotype seen clearly in
LgDel embryos—4th pharyngeal arch artery hypoplasia
(PAA4; Fig. 6A). In Shh+/2 embryos, expression of Smo,
Ptch1 and Ptch2, all Shh-regulated (44), are not altered (P ≥
0.4, n ¼ 5), even though Shh declines by 40% (P ≤ 0.007,
n ¼ 6 Shh+/2; 4 WT), and Gli3 increases by 16% (P ≤
0.03; Fig. 6B). We saw no gross phenotypic changes in
LgDel:Shh+/2 embryos (data not shown). Forty-four percent
(4/9) of Shh+/2:LgDel embryos have a hypoplastic or absent
PAA4, statistically indistinguishable from the 57% PAA4 fre-
quency in LgDel littermates (P ≤ 0.2; Table 1). We selected
Gli3 as a likely Shh gain-of-function mutation based upon
its established role in Shh-mediated repression (45). Surpris-
ingly, Shh itself as well as two positive regulators of Shh
signaling are reduced rather than increased—the anticipated
consequence of release of repression—in Gli3+/Xtj and
Gli3Xtj/Xtj embryos (Fig. 6C). In Gli3+/Xtj embryos, Gli1
was reduced to 61% of WT (P ≤ 0.03, n ¼ 10 Gli3+/Xtj; 8
WT). In Gli3Xtj/Xtj embryos, Gli1, Smo and Shh were
reduced to 29, 53 and 60% of WT (P ≤ 0.02 n ¼ 5 Gli3Xtj/
Xtj; 8 WT), respectively. Together these data suggest that
Gli3 mutation results in diminished, rather than enhanced
Shh signaling. One hundred percent of Gli3Xtj/+:LgDel (n ¼
8/8) and Gli3Xtj/Xtj:LgDel (n ¼ 6/6) embryos have significant
PAA4 disruptions seen at significantly lower frequency or
not at all in WT, LgDel or Gli3 mutants (Fig. 6D;
Gli3+/Xtj:LgDel P ≤ 0.005; Gli3Xtj/Xt:LgDel P ≤ 0.01;
Table 1). Thus, in LgDel embryos, diminished Shh in
Shh+/2 mutants is insufficient to modify 22q11DS pheno-
types, whereas decreased Shh signaling in cyclopamine
treated LgDel as well as Gli3Xtj:LgDel embryos reaches a
threshold for phenotypic change not seen in WT littermates,
single mutants or Tbx1+/2 embryos.
22q11 gene dosage and RA signaling interact during
morphogenesis
If a proposed ‘phenocopy’ of 22q11DS due to RA
loss-of-function (13) reflects linear relationships between RA
signaling and 22q11 gene dosage, enhanced signaling should
Figure 6. Genetic alteration of Shh signaling selectively modifies gene expres-
sion and cardiac phenotypes in LgDel embryos. (A) Lower magnification
Z-stack confocal images showing the heart and pharyngeal arch arteries
(PAA) in E10.5 WT and LgDel embryos stained for the cell-adhesion mol-
ecule PECAM/CD31, and imaged whole. The primary LgDel phenotype is a
hypoplastic PAA4 (compare at double arrowheads). (B) Changes in expression
levels of Shh-regulated genes in E10.5 Shh+/2 embryos. Solid yellow bars in-
dicate significant changes. (C) Changes in a broader range of Shh-regulated
genes in E10.5 Gli3+/Xtj (left hand bar in each pair) and Gli3Xtj/Xtj (right
hand bar in each pair) embryos. Hatched (Gli3+/Xtj) and solid (Gli3Xtj/Xtj)
yellow bars indicate significant changes. (D) Higher magnification confocal
images of PECAM labeled PAAs in Gli3Xtj/Xtj, LgDel:Gli3+/Xtj (middle)
and LgDel:Gli3Xtj/Xtj (right). The PAAs in the Gli3Xtj/Xtj are comparable to
WT. Compound mutants have increasingly severe and more frequent PAA4
and PAA6 hypoplasia not seen in LgDel or Gli3+/Xtj or Gli3Xtj/Xtj mutant
embryos (Table 1). The tracings in the lower panels highlight primary pheno-
typic changes.
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result in rescue, and decreased signaling should have little in-
fluence on 22q11DS phenotypes. This would be consistent
with diminished levels of RA signaling we have found in
LgDel embryos. If, however, the relationship between 22q11
and RA signaling reflects more complex homeostatic interac-
tions with 22q11 gene dosage, either raising or lowering RA
signaling could lead to significantly enhanced or novel pheno-
types.
Modest, sustained doses of all trans RA delivered via ma-
ternal circulation between E8.5 and E10.5, similar to those
reported to rescue RA-related mutant phenotypes (46),
substantially increase RA signaling levels. Based on
DR5-RARE quantification, 48 h RA exposure increases RA
signaling in the head/forebrain by 73% for WT (n ¼ 4; P ≤
0.02) and 50% for LgDel embryos (n ¼ 4; P ≤ 0.02). In the
heart, there is a divergent response: LgDel embryos have a sig-
nificant increase (38%, n ¼ 4, P ≤ 0.03); WT embryos do not
(18%, n ¼ 4 P ≥ 0.14). Thus, diminished 22q11 gene dosage
differentially modulates cranial versus cardiac RA signaling.
These changes are accompanied by disruption of cranial
and cardiovascular morphogenesis in RA-exposed LgDel
embryos not seen in RA-exposed WT littermates or untreated
LgDel embryos (Fig. 7A). RA-treated LgDel embryos have
significantly increased neural tube closure defects—a pheno-
type not routinely associated with 22q11DS [but see Nickel
and Magenis (47)] 11/15 LgDel + RA versus 0/39 WT +
RA and 0/33 LgDel untreated are exencephalic (P ≤ 0.0001;
Table 2). Cardiac phenotypes are also modified. PAA dysmor-
phology is substantially enhanced in RA-treated LgDel versus
WT littermates or untreated LgDel embryos (Fig. 7B; Table 3).
PAA4 defects reach 100%, and PAA4 is frequently absent (5/8
in LgDel + RA; 0/8 LgDel; P ≤ 0.01; Fig. 7B, Table 3). These
novel anomalies are not seen at significantly higher levels in
RA-treated Tbx1+/2 embryos (Tables 2 and 3). Thus, dimin-
ished 22q11 gene dosage beyond Tbx1 interacts with elevated
RA signaling in the developing brain and heart to yield sub-
stantially altered phenotypes.
We next asked whether increased RA signaling in the
LgDel differentially modifies RA-signaling gene expression.
Expression of several genes that are either unchanged
(Raldh1) or diminished in LgDel embryos (Raldh2, Rara,
Figure 7. Diminished dosage of 22q11 genes sensitizes embryos to sub-
teratogenic RA exposure. (A) RA-exposed LgDel (top half) are substantially
more dysmorphic and smaller in size than WT littermates (bottom half; 15
LgDel and 19 WT littermate embryos from four litters). (B) Confocal
images, and accompanying tracings, of PECAM-labeled PAAs in untreated
WT, LgDel and Tbx1 embryos show the normal pattern (WT and WT +
RA) and varying degrees of dysmorphology in LgDel and Tbx1+/2 as well
as LgDel and Tbx1+/2 treated with RA. (C) Distinct expression changes in
RA signaling-related genes in LgDel embryos. Brackets and asterisks indicate
significant differences in expression levels between the four groups (WT –
and + RA; LgDel – and + RA). (D) Increased RA between E8 and E10
does not significantly alter 22q11 gene expression beyond 50% in E10.5
LgDel embryos.
Table 1. The consequences of genetically altered Shh signaling via the Shh or
the Gli3Xtj mutation on pharyngeal arch artery 4 (PAA4) morphogenesis in
LgDel embryos, based on frequency of hypoplastic or absent PAA4
4th arch phenotype
Total Normal Hypoplastic Absent
WT 33 33 0 0
Lgdel 33 15 18 0
Shh2/+ 9 9 0 0
LgDel;Shh2/+ 9 5 3 1
Gli3XtJ/+ 9 9 0 0
Gli3XtJ/+;Lgdel 8 0 4 4
Gli3XtJ/XtJ 5 5 0 0
Gli3XtJ/XtJ;LgDel 4 0 1 3
Single or compound genotypes are listed at left, and frequency of PAA4
dysmorphology is given in middle and right hand columns.
306 Human Molecular Genetics, 2013, Vol. 22, No. 2
Rarb; Fig. 1) is further decreased by RA exposure (Fig. 7C;
n ¼ 3 LgDel + RA, 3 LgDel, 3 WT + RA, 3 WT; P ≤ 0.04
Raldh1, 0.02 Raldh2, 0.005 Rara, 0.03 Rarb). Indeed, for
two RA-regulated retinoid receptors, Rara and Rarb, RA
has divergent effects in WT and LgDel embryos. In contrast,
despite some indication that RA influences 22q11 gene expres-
sion (Fig. 4 and Supplementary Material, Fig. S3), there is no
significant change for any 22q11 genes in RA-treated LgDel
embryos beyond the 50% diminished expression seen in
untreated LgDel embryos (Fig. 7D; n ¼ 3 LgDel + RA, 3
Lgdel; see also Supplementary Material, Fig. S3). Therefore,
diminished 22q11 gene dosage differentially alters the tran-
scriptional response to elevated RA signaling without modify-
ing 22q11 gene expression.
Finally, we asked whether LgDel embryos are also sensi-
tized to a genetic mutation that modestly lowers RA signaling.
E10.5 mouse embryos carrying a heterozygous Raldh2 muta-
tion (48) have 20% diminished RA signaling levels based
on quantitative assessment using the DR5-RARE reporter
(P ≤ 0.002, n ¼ 4), without obvious dysmorphology. This
change has consequences for RA-regulated gene expression
in Raldh2+/2 as well as Raldh2+/2:LgDel embryos
(Fig. 8A). In each of the three genotypes, levels are often
significantly lower than WT (asterisks); however, there are
no significant differences between Raldh2+/2 and Raldh2+/2:
LgDel embryos. Moreover, selected 22q11 genes (apparently
RA-regulated; Fig. 4 and Supplementary Material, Fig. S3)
do not decline beyond the 50% LgDel values in either add-
itional genotype (Fig. 8A, right). To determine if a potentially
compound decrease of RA signaling due to heterozygous
Raldh2 mutation and diminished 22q11 dosage results in
novel or enhanced 22q11DS related phenotypes, we assessed
neural tube closure and PAA4 development in Raldh2+/2:
LgDel compound mutants. Thirty-six percent (4/11) of
Raldh2+/2:LgDel mutants exhibit exencephaly not observed
in LgDel, Raldh2+/2 or WT embryos (P ≤ 0.02; Fig. 8B
and Table 3). One hundred percent of Raldh2+/2;LgDel
embryos have PAA4 dysmorphogenesis, whereas littermate
LgDel embryos have the expected 57% frequency (Table 3;
P ¼ 0.02). In compound mutants, PAA4 phenotypes
(Fig. 8C) include hypoplasia (4/8; 50%) as well as absence
(4/8; 50%). These phenotypes are seen at significantly
higher frequencies in Raldh2+/2;LgDel embryos versus
single or compound Raldh2+/2:Tbx1+/2 mutant embryos
(P ≤ 0.01; Table 3; Fig. 8D and E). The frequency of PAA4
Table 3. The consequences of pharmacological or genetic alteration of RA sig-
naling for PAA4 morphogenesis in LgDel embryos
4th arch phenotype
Total Normal Hypoplastic Absent
WT 33 33 0 0
WT + RA 11 8 3 0
LgDel 33 15 18 0
LgDel + RA 8 0 3 5
Tbx1+/2 10 6 4 0
Tbx1+/2 + RA 7 3 2 2
Raldh2 +/2 14 13 1 0
LD;Raldh2+/2 8 2 2 4
Tbx1;Raldh2+/2 9 3 6 0
Genotypes and RA treatment groups are identified at left, and the frequency of
PAA dysmorphology, scored as hypoplastic or absent, is listed in the middle
and right hand columns.
Table 2. The consequences of pharmacological or genetic alteration of RA
signaling for neural tube closure in LgDel embryos, based on scoring for
execephaly at E10.5
Total Normal Exencephalic
WT 39 39 0
WT + RA 19 19 0
LgDel 33 33 0
LgDel + RA 15 4 11
Tbx1+/2 10 10 0
Tbx1+/2 + RA 7 7 0
Raldh2+/2 14 14 0
LgDel;Raldh2+/2 11 7 4
Tbx1+/2;Raldh2+/2 5 5 0
Genotypes and RA treatment groups are identified at left, and the frequency of
exencephaly is recorded at right.
Figure 8. Genetic alteration of RA signaling selectively modifies cranial and
cardiac phenotypes in LgDel embryos. (A) RA regulated RA signaling genes
are diminished in LgDel and LgDel:Raldh2+/2embryos. Asterisks indicate
RA-regulated or 22q11 genes whose expression is significantly altered from
WT levels in Raldh2+/2, LgDel and Raldh2+/2:LgDel compound embryos.
There is no apparent interaction between the two genotypes for further
change in RA-regulated genes. (B) Morphogenetic phenotypes, including
smaller limb buds (lb) and branchial arches (ba), diminished frontonasal
processes (fnp), and exencephaly (arrowheads) are seen in compound
LgDel:Raldh2+/2 embryos. (C) Confocal image and accompanying cartoon
of PAAs in LgDel:Raldh2+/2 embryos show PAA4 absence. (D) Tbx1+/2:
Raldh2+/2 compound mutant embryos have no observable gross phenotypes.
(E) PAA morphology in Tbx1+/2:Raldh2+/2 compound mutants.
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hypoplasia (66%) is statistically indistinguishable in Tbx1+/2
and Raldh2+/2:Tbx1+/2 embryos (n ¼ 6/9 Raldh2+/2:
Tbx1+/2; 4/10 Tbx1+/2; P ¼ 0.2). Thus, diminished 22q11
gene dosage sensitizes LgDel, but not Tbx1+/2 embryos to
both elevated and diminished RA signaling, resulting in
novel or more severe 22q11DS-related cranial and cardiac
phenotypes.
DISCUSSION
When 22q11 gene expression is diminished, signaling via Shh
and RA is altered in the developing brain and heart. These
changes may directly influence embryonic phenotypes asso-
ciated with 22q11DS; however, they also enhance sensitivity
of cranial and cardiac development to additional Shh or RA
signaling variation. Alteration of RA and Shh signaling that
is minimally disruptive in WT or Tbx1 mutant embryos
causes more frequent, severe or novel phenotypes in LgDel
embryos. Apparently, full dosage of multiple 22q11 genes
establishes an optimal adaptive range for Shh and RA signal-
ing in the developing head and heart. 22q11 deletion constricts
this range and diminishes embryonic tolerance to signaling
variability. Thus, the mutable frequency and severity of
22q11DS phenotypes—particularly forebrain and heart anom-
alies—likely reflects, in part, consequences of otherwise rela-
tively benign environmental exposure or genetic variation that
alters morphogenetic signaling beyond adaptive levels that are
constricted by diminished 22q11 gene dosage.
Quantitative alterations of morphogenetic signaling in
22q11DS
Four essential morphogenetic signaling pathways—activated
by Shh, RA, Fgfs and Bmps—have been associated with
22q11DS pathogenesis for the last two decades (12,13,15,
16,18,23,33,49,50). Some pathways have been implicated
based upon apparent phenotypic similarities in mutant mice
and 22q11DS (49,50), while altered expression patterns of
selected target genes, especially in Tbx1 mutant mice, indicate
contributions by others (16–19,33,51). We found that dimin-
ished 22q11 gene dosage, beyond Tbx1, regulates expression
levels of Shh, RA and Bmp—and to a lesser extent
Fgf—signaling genes. These pathways in turn regulate
22q11 gene expression levels. This apparently reciprocal regu-
lation, however, is limited. Altered Shh or RA signaling in
LgDel embryos does not further reduce 22q11 gene expression
(with one exception) beyond 50%. Finally, the magnitude or
direction of changes in signaling and signal-dependent
22q11 gene expression varies at 22q11DS phenotypic sites in-
cluding the brain and heart. Such distinctions provide a new
framework for considering complex and variable 22q11DS
phenotypes. Local quantitative changes in signaling and
22q11 gene dosage during mid-gestation likely modulate mor-
phogenetic interactions between mesenchymal (M) and epithe-
lial (E) tissues at these sites. Phenotypes may vary due to
altered M/E signaling that idiosyncratically further modifies
morphogenetic signaling activity in the context of diminished
22q11 dosage.
22q11 gene dosage and Shh signaling interact during
morphogenesis
We found that diminished 22q11 gene dosage—exclusive of
Tbx1—disrupts Shh signaling levels in the heart, and sensitizes
embryos to deleterious effects of altered Shh signaling. In the
heart, epithelial Shh may maintain a minimal level of 22q11
gene expression in the mesenchyme and establish feedback
that further regulates epithelial Shh signaling centers (52).
Diminished dosage of 22q11 genes may disrupt this relation-
ship leading to the local increase in cardiac Shh and Shh sig-
naling we found. This may reflect altered inductive capacity of
neural crest derived cardiac mesenchyme (12,14,46,53) with
22q11-related epithelial disruption of Shh leading to additional
mesenchymal changes. Shh is required for cardiac neural crest
survival (54) and maintenance of heart field progenitor prolif-
eration (55). Thus, the local gain in Shh message and Shh sig-
naling in the heart (or stability in the forebrain despite
embryo-wide diminished Shh expression in the LgDel) may
defray or modify some consequences of decreased 22q11
gene dosage (16,56). Indeed, compensatory changes in Shh
signaling may be an M/E-mediated local response to embryo-
wide Shh decline in the context of diminished 22q11 gene
dosage.
When Shh signaling is disrupted briefly but substantially—
based upon decline in levels of Ptch1, Ptch2 and Smo—
following cyclopamine exposure, non-axial morphogenesis
fails in LgDel but not WT or Tbx1+/2embryos. Therefore,
diminished 22q11 gene dosage beyond Tbx1 sensitizes some
essential aspect of Shh-mediated M/E-dependent morphogen-
esis at 22q11DS phenotypic sites. Cell proliferation may be
a key target, since both Shh signaling and several 22q11
genes enhance proliferation (9,57). The combined conse-
quences of cyclopamine-altered Shh signaling and diminished
22q11 dosage, especially in the mesenchyme where Shh is
mitogenic (58) and 22q11 gene expression is enhanced (11)
may overwhelm morphogenesis. Shh signaling is apparently
diminished by Gli3 mutation based on declines in the Gli1 tran-
scriptional activator (Gli3+/Xtj and Gli3Xtj/Xtj) as well as Smo
and Shh itself (Gli3Xtj/Xtj). Partial or complete loss of Gli3
activator or repressor function may disrupt a precarious equilib-
rium of already modified Shh signaling leading to more severe
phenotypes. Apparently, 22q11 deletion compromises the
normal balance of Shh signaling in the heart, and thus alters
the threshold for cardiac morphogenetic modulation by add-
itional genetic or environmental changes in Shh signaling.
RA signaling pathways are disrupted by 22q11 deletion
Appropriate 22q11 gene dosage—again exclusive of Tbx1—
maintains the integrity of RA signaling in LgDel embryos.
Decreased expression of two out of three major RA synthetic
enzymes, Raldh2 and Raldh3, essential for brain and heart de-
velopment (59) as well as two RA-regulated receptors, Rarb
(60) and Rara, in LgDel embryos, all expressed primarily in
the mesenchyme at 22q11DS phenotypic sites (11,52,61),
may modify mesenchymal RA production (52,62) thus
disrupting RA signaling in adjacent epithelia in LgDel
embryos. Such changes might compromise proliferation or dif-
ferentiation in progenitors that rely upon RA signaling in the
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brain (63) and cardiac outflow tract (64). Thus, deletion of
multiple 22q11 genes critical for RA signaling, especially
22q11 genes expressed selectively or exclusively in cranial
and pharyngeal arch mesenchyme (11 and unpublished data),
may interfere with the ability of cranial or cardiac tissues to
generate, transmit or metabolize RA resulting in locally
decreased RA signaling and brain and heart dysmorphogenesis.
We found that a sub-teratogenic increase in RA signaling
(50%) or a modest decline (20%) due to heterozygous
mutation of Raldh2 has surprisingly similar morphogenetic
consequences in LgDel but not WT, Raldh2+/2 or Tbx1+/2
embryos. This accords with many observations that demon-
strate similar effects of increased or diminished RA signaling
on morphogenesis (65). In both LgDel + RA and
LgDel:Raldh2+/2 embryos, RA-regulated genes have distinct
transcriptional responses when 22q11 deletion and altered RA
signaling are combined. Nevertheless, in both instances, there
is novel occurrence of exencephaly as well as increased fre-
quency and severity of PAA dysmorphogenesis. This consist-
ent outcome, despite divergent RA-mediated transcriptional
regulation, demonstrates—contrary to earlier claims based
on studies in Tbx1 mutant embryos (18,33,66)—that singular
changes in RA-sensitive genes like Rarb, Rara or other RA
cofactors, are unlikely to explain specific cranial or cardiovas-
cular phenotypes as 22q11DS phenocopies.
Morphogenetic disruptions in LgDel:Raldh2+/2 embryos
cannot be explained by modulation of RA signaling levels or
related RA signaling gene expression alone. Indeed, expres-
sion of key RA signaling genes in the LgDel:Raldh2+/2 com-
pound mutant embryos is essentially indistinguishable from
that in Raldh2+/2 embryos. It is likely that transcriptional
disruptions in the LgDel:Raldh2+/2 engage multiple targets
including additional signaling pathways and downstream
effectors. Diminished 22q11 gene expression alters key Shh
and BMP signaling genes in parallel with changes in RA
signaling. These pathways, whose activity is known to be
modified in the forebrain or heart of Raldh2 mutant mice
(67,68), and many others, might be more significantly compro-
mised by simultaneous 22q11 gene deletion and heterozygous
Raldh2 mutation than either alone. A broader analysis of tran-
scriptome changes in single and compound mutants may iden-
tify such synergistic, quantitative disruptions of homeostatic
regulation of networks beyond those directly engaged in RA
signaling. Thus, additive disruptions, beginning with a single
signaling pathway and expanding to include multiple gene
networks, may contribute to phenotypic variation seen in
22q11DS.
22q11 gene dosage establishes a dynamic range for
morphogenetic interactions
Our data show that full 22q11 gene dosage—exclusive of
Tbx1—maintains an adaptive range for morphogenetic signal-
ing in the heart and brain (Fig. 9). Accordingly, when 22q11
gene dosage is diminished in 22q11DS, or elevated, as in
instances of 22q11 duplication (69,70), M/E interactions that
drive heart and brain morphogenesis no longer accommodate
modest to substantial changes in Shh and RA signaling that
otherwise do not result in phenotypes. A broad range of
altered Shh signaling, from 20 to 80% based on measurement
of Ptch1, Ptch2, Gli1 or Smo (Fig. 9) is tolerated fairly well by
WT, Shh+/2, Gli3+/2 or Gli32/2 but not LgDel embryos.
Similarly, a 50% increase or 20% decline defines a range of
RA signaling that can be accommodated in the head and
heart of WT and Tbx1+/2, but not LgDel embryos (Fig. 9).
Thus, otherwise benign changes of Shh or RA signaling may
explain a substantial amount of 22q11DS phenotypic variation
(2). Such changes may arise from fairly common environmen-
tal and genetic disruptions (71,72), and these aberrations when
combined with diminished 22q11 gene dosage likely modulate
22q11DS phenotypic severity. Diminished dosage of Tbx1
alone does not constrict the adaptive range for Shh and RA
signaling; instead, diminished dosage of additional 22q11
genes—the fundamental change in 22q11DS patients—is ne-
cessary. Accordingly, deletion of 22q11 genes beyond Tbx1
likely interacts with otherwise benign alterations in morpho-
genetic signaling to enhance clinically significant phenotypes
in individuals with 22q11DS.
MATERIALS AND METHODS
Mice
The University of North Carolina at Chapel Hill (UNC-CH)
Division of Laboratory Animal Medicine or The George
Figure 9. Diminished dosage of 22q11 genes constricts an adaptive range for
optimal morphogenetic signaling. First row: Optimal adaptive range for mor-
phogenetic signaling. In this model, signaling via Shh, RA (or, potentially,
other morphogenetic signals that act at M/E sites) might fall a considerable
amount below or above an optimal level (100%) before phenotypic conse-
quences are seen. Second row: Adaptive range for Shh signaling buffers
against phenotypic changes when Shh signaling is reduced by as much
as 86% in WT embryos. Third row: Diminished 22q11 gene expression
constricts the adaptive range of Shh signaling and modifies levels of aberrant
signaling that can be tolerated without phenotypic change. Fourth row: The
adaptive range for RA signaling in WT extends from 80 to 173% WT
signaling levels, based upon our data. Fifth row: The adaptive range for RA
signaling is constricted when 22q11 gene expression is diminished, and
novel or more severe phenotypes are seen.
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Washington (GW) University Animal Research Facility
maintained colonies of WT CD-1, Shh+/2, Gli3+/2, Fgf8neo/+,
Raldh2+/2, Nog+/2, Tbx1+/2, DR5-RARE:bgal and
Ptch2:bgal (Deltagen) mice. All mutant lines were maintained
on a C57BL6/J6 background. We also used Tbx1 mutants on
an S129 background for cyclopamine exposure experiments.
The LgDel mutation [heterozygous deletion on mmchr.16 from
Idd to Hira (30)] was transmitted paternally. Timed-
pregnant females (vaginal plug day ¼ E0.5) were sacrificed
by rapid cervical dislocation and embryos were dissected and
collected for expression, signaling or phenotypic analysis. All
procedures were reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC) at UNC-CH or GW.
Quantitative PCR (qPCR)
E10.5 embryos (or dissected embryonic regions as described)
were harvested, dissected and homogenized in TRIzol (Invi-
trogen). Total RNA was isolated, and cDNA synthesized and
qPCR performed as described previously (10). Primers for
qPCR are listed in Supplementary Material, Table S1. Expres-
sion of each transcript is displayed as the fraction of the
expression in the WT and untreated cohort.
Statistical analysis
Mean expression values between genotypes or treatments were
compared using Student’s unpaired t-test. Fisher’s exact tests,
used to compare phenotypic outcomes in groups with distinct
genotypes, were conducted using MS Excel software.
Immunohistochemistry and ISH
Embryos were fixed overnight, and ISH and imaging was
performed as described previously (9). For whole mount
immuno-staining, embryos were dehydrated in methanol,
stored at -808C and freeze-thawed (5×). Specimens were
rehydrated (PBS) and then incubated overnight at 48C in 5%
DMSO, 0.2% Triton X-100 and 5% normal goat serum in
PBS. Following primary antibody incubation overnight at
48C (Rat anti-CD31/PECAM; BD-Pharmingen), specimens
were rinsed and labeled with Alexa-Fluor 488 or 546 conju-
gated anti-rat secondary antibodies overnight (48C). Finally,
embryos were rinsed and dehydrated in MeOH, cleared with
2:1 benzyl alcohol:benzyl benzoate and imaged on a Zeiss
LSM 510 confocal microscope. 2D projections of Z-Stacks
were created using Zeiss LSM image processing software.
b-galactosidase staining and enzymatic activity
quantification
Embryos were harvested and dissected in PBS and either fixed
in 0.1% glutaraldyhyde for whole mount staining or lysed in 2
× ONPG (ortho-Nitrophenyl-bgalactoside) lysis buffer
(Promega) for soluble bgal assays as described previously
(62). bgal activity was detected as a function of ONPG en-
zymatic hydrolysis analyzed at 420 nm on an ELX808 ultra
microplate reader (Bio-Tek Instruments).
Pharmacological treatments
To evaluate regulation of 22q11 genes in WT embryos, preg-
nant WT dams (CD-1 strain) were injected with 10 mg/kg RA
(Sigma), 100 mg/kg DEAB (Sigma), 80 mg/kg cyclopamine
(LC Laboratories), 50 mg/kg PD173074 (Sigma) or 10 mg/
kg dorsomorphin (Sigma) at E9.5 and embryos harvested
24 h later. To evaluate consequences of disrupted Shh or RA
signaling for morphogenesis, pregnant LgDel dams were
injected with RA (10 mg/kg on E8.5 and 20 mg/kg on E9.5)
or cyclopamine (80 mg/kg) twice (E8.5 and E9.5) over 48 h
period before harvesting at E10.5.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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